Company Overview and News

 
KLCI rises 0.24% as blue chips lift

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047

 
KLCI pares gains, stays up 0.28%

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF

 
Perstima share price up on stellar earnings

2018-08-02 thestar.com.my
As of mid-day, the stock rose 6.8% to RM5.17, and total shares traded for the day amounted to 187,500 shares.
5436 BSMAF 1818

 
KLCI reverses loss, edges up in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI reversed its earlier loss and climbed into positive territory at the midday break today, tracking gains at the regional markets.
HLFBF 7036 7374 5134 GMALY 2852 5029 5347 0035 4715 TNABY 5208 PNAGF 1929 GMALF 1082 ORHLF 6033 7123 5436 4006 PNADF 0026 5819 TNABF

 
Perstima emerge as top gainer on Bursa Malaysia this morning

2018-08-01 malaymail
KUALA LUMPUR, Aug 1 — Perusahaan Sadur Timah Malaysia (Perstima) emerged the top gainer on Bursa Malaysia this morning on the back of news that its net profit for the first quarter ended March 31, 2018 soared 328 per cent to RM12.14 million from RM2.84 million from the corresponding period of the previous year.
5436 BSMAF 1818

 
Perstima jumps 6.20% on impressive 1Q earnings

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Tinplate exporter Perusahaan Sadur Timah Malaysia Bhd (Perstima) rose 6.20% this morning after its first quarter net profit jumped by 328% to RM12.14 million from RM2.84 million a year earlier, thanks to higher profit margins despite lower sales volume. Quarterly revenue rose slightly to RM238.83 million from RM237.5 million previously.
5436

 
KLCI pares loss, attempts to climb higher in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI pared some its loss at mid-morning today and made an attempt to climb higher in line with the gains at most regional markets.
UPBMF 8621 7113 TPGVF BATS 4162 2089 6033 7123 TGLVY 5436 PNADF 5347 0035 0026 5208 TNABY 5819 TNABF PNAGF GEBHF

 
KLCI seen starting off August on a positive note, support at 1,770-level

2018-07-31 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI is seen starting off August on a positive note today, in line with the overnight gains at most global markets, with support at the 1,770-point level.
5436 5216 0035 7158 5151 7022 GBTKF

 
Scomi Group, YTL Hospitality REIT, Serba Dinamik, Perstima, Globetronics, Opcom, Halex and Datasonic

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Based on corporate announcements and news flow today, companies in focus on Wednesday (Aug 1) may include: Scomi Group Bhd, YTL Hospitality Real Estate Investment Trust (REIT), Serba Dinamik Holdings Bhd, Perusahaan Sadur Timah Malaysia Bhd, Globetronics Technology Bhd, Opcom Holdings Bhd, Halex Holdings Bhd and Datasonic Group Bhd.
SLLXF 5436 5216 4863 0035 5109 7158 HIL MYTEF 5151 7022 GBTKF

 
Perstima’s 1Q net profit jumps by 328 percent on higher margins

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Tinplate exporter Perusahaan Sadur Timah Malaysia Bhd’s (Perstima) first quarter net profit jumped by 328 percent to RM12.14 million from RM2.84 million a year earlier, thanks to higher profit margins despite lower sales volume.
5436 BSMAF 1818

 
KLCI remains muted despite uptrend at regional markets

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): The FBM KLCI clawed into positive territory at mid-morning but remained somewhat muted against the backdrop of the positive regional markets.
HLFBF 7052 UPBMF 4065 1082 9679 5245 2089 5255 5436 1201 3301 8613 2739 2836

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...